MEMBERS FUNDING ANNOUNCEMENTS.
Call for tenders HADEA/2023/OP/0036: Speed up the development of and access to innovative medical countermeasures
Issued by: Health Emergency Preparedness and Response Authority (HERA)
Notice Number: HADEA/2023/OP/0036
First Available Due Date: September 22, 2023
Expiration date: December 04, 2023
This call for tenders aims at purchasing services to speed up the development of and support the access to medical countermeasures which address HERA’s priority threats. To accelerate development and support access to MCMs, the requested services include the provision of clinical and concurrent non-clinical development services and the priority right to purchase the promising products (Investigational Medicinal Product – IMP for lots 1, 2 and 3 and product for lot 4), that shall allow bringing innovative products to the market and ensure EU/EEA access to them.
Release date: September 22, 2023
Notice of Special Interest (NOSI): Halting Tuberculosis (TB) Transmission
Issued by: National Institute of Allergy and Infectious Diseases (NIAID)
Notice Number: NOT-AI-22-064
First Available Due Date: February 05, 2023
Expiration date: January 08, 2026
The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in accepting applications that aim to understand the critical drivers of Tuberculosis (TB) transmission at the individual and population levels in high-burden settings. Applicants are encouraged to develop effective methods to measure rates of TB transmission that rely on an increased understanding of the biomedical basis of transmission and related risk factors and to develop and assess potential interventions, including low-cost and low-tech options, to prevent TB transmission.
...Efforts to control this global epidemic have been hampered by inadequate understanding of the underlying epidemiology and biologic mechanisms of transmission and lack of effective interventions to prevent TB transmission. The key drivers of transmission are not completely understood and developing interventions has thus far remained unattainable.
TB disease incidence appears to be driven more by recent transmission rather than by reactivation events, so identification of biomarkers of recent transmission would allow identification of people more likely to develop active disease. The TB transmission cycle is extremely complex with multiple contributing host/pathogen/micro-environmental factors. Improved knowledge of these interactions and factors driving transmission would allow efficacious approaches for preventing transmission, to be developed or improved and adapted for a broad scale-up. This is particularly timely, as advances in understanding aerobiology and transmission for COVID may be leveraged to understand and prevent transmission of TB.
Release date: September 20, 2022
Notice of Special Interest (NOSI): Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design
Release date: September 20, 2020
Expiration date: January 08, 2023
The purpose of this Notice of Special Interest (NOSI) is to stimulate innovative studies to identify and understand the immune responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Studies may focus on any stage of mycobacterial infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines and may include HIV-infected or uninfected individuals.
Research supported under this NOSI should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications that include characterization of the timing, anatomical location, and contribution to disease outcome, of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination are sought. This research is expected to advance understanding of immune mechanisms in Mtb infection/vaccination and contribute to the advancement of new TB vaccines, including in populations also infected with HIV.
Posted: December 17, 2020